Abstract 740
Background
Poly ADP-ribose polymerase inhibitors (PARPIs) have received US and European regulatory approvals for the treatment of BRCA-associated ovarian cancer. The approval of PARPIs in rapid succession has resulted in a paradigm shift in the management of recurrent ovarian cancer.
Methods
2,116 ovarian cancer patients (pts) in advanced/metastatic (adv/met) lines of therapy from Jan 2016 to Oct 2018 in EU5 (France, Germany, Spain, Italy, UK) were identified within Oncology Dynamics, an IQVIA oncology-syndicated cross-sectional survey collecting anonymized patient-level data. Maintenance therapy was also investigated in 534 pts.
Results
Platinum-based regimens for the treatment of adv/met ovarian cancer pts decreased from 56% in 2017 to 50% by Oct 2018. In contrast, the use of PARPIs increased from 9% to 14%. A reduction in the administration of PARPIs was noted in all platinum-based regimens (▾15% and ▾13% in 2nd and 3rd+ lines adv/met) and in non-platinum chemotherapy (▾8% and ▾9% in 2nd and 3rd+ lines adv/met). However, in platinum-sensitive ovarian cancer pts, there has been an increase of PARPIs in 2nd and 3rd+ lines (given to 27% and 29% pts, respectively). The use in the 1st line adv/met setting has also increased by 3% (administered to 8% of pts). Prior to PARPIs, most of the pts were treated with platinum-based regimens (97%). As maintenance treatment, PARPIs have been most used in 2nd (26%) and 3rd+ line (22%) in platinum-sensitive adv/met ovarian cancer. 93% of adv/met ovarian cancer pts treated with PARPIs had an ECOG status of ≤ 1 and most suffered no comorbidities (50%). Peritoneum was the most common metastatic site (63%), followed by lymph nodes (38%). Nearly all pts had been tested for BRCA1/2 and 79% of them presented mutations. Progression was the most common reason for stopping treatment with PARPIs (72%); and anaemia, nausea, vomiting, neutropenia, and rash were the most common side effects on historic patient records.
Conclusions
PARPIs have certainly shown a meaningful impact on progression-free survival in pts with platinum-sensitive recurrent ovarian cancer, without any deleterious impact on the quality of life. The use of PARPIs is rising in the platinum-sensitive ovarian cancer population in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA.
Funding
IQVIA.
Disclosure
A. Martinez de Pinillos: Full / Part-time employment: IQVIA C. Anger: Full / Part-time employment: IQVIA L. Mendoza: Full / Part-time employment: IQVIA
Resources from the same session
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract